Retrophin Company Profile (NASDAQ:RTRX)

About Retrophin

Retrophin logoRetrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RTRX
  • CUSIP:
Key Metrics:
  • Previous Close: $20.58
  • 50 Day Moving Average: $21.96
  • 200 Day Moving Average: $18.11
  • 52-Week Range: $36,731,000.00 - $11.60
  • Trailing P/E Ratio: 8.44
  • Foreward P/E Ratio: -26.73
  • P/E Growth: 12.16
  • Market Cap: $763.64M
  • Outstanding Shares: 36,731,000
  • Beta: 1.02
  • Net Margins: 83.57%
  • Return on Equity: -0.52%
  • Return on Assets: -0.31%
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 3.75%
  • Quick Ratio: 3.72%
Additional Links:
Companies Related to Retrophin:

Analyst Ratings

Consensus Ratings for Retrophin (NASDAQ:RTRX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.33 (61.97% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
DateFirmActionRatingPrice TargetDetails
9/9/2016JMP SecuritiesReiterated RatingOutperform$28.00View Rating Details
9/8/2016BMO Capital MarketsReiterated RatingOutperform$28.00 -> $40.00View Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00View Rating Details
6/4/2015Deutsche Bank AGBoost Price TargetBuy$52.00 -> $55.00View Rating Details
5/23/2015NomuraReiterated RatingBuy$31.00 -> $34.00View Rating Details
5/15/2015Avondale PartnersInitiated CoverageOutperform$39.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Retrophin (NASDAQ:RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q2($0.23)$0.07$32.73 million$33.30 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.40 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)ViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Retrophin (NASDAQ:RTRX)
Current Year EPS Consensus Estimate: $-0.56 EPS
Next Year EPS Consensus Estimate: $-0.77 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.26)($0.26)($0.26)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.24)($0.24)($0.24)
Q4 20161($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)


Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Retrophin (NASDAQ:RTRX)
Insider Ownership Percentage: 2.41%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Retrophin (NASDAQ:RTRX)
News IconRetrophin, Inc. (RTRX) Analyst Review - NewsDen - NewsDen (NASDAQ:RTRX) - October 22 at 11:10 AM logoRetrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : October 21, 2016 (NASDAQ:RTRX) - October 21 at 10:40 AM logoRetrophin to Report Third Quarter 2016 Financial Results (NASDAQ:RTRX) - October 20 at 7:25 PM
News IconRetrophin, Inc. (NASDAQ:RTRX) Upcoming Earnings: What matter ... - The Voice Registrar (NASDAQ:RTRX) - October 18 at 6:59 PM
News IconLatest Analyst Ratings For Retrophin, Inc. (RTRX) - The De Soto Edge (NASDAQ:RTRX) - October 17 at 7:00 PM
News IconShare Value Diminishing Over Past Month: Retrophin, Inc ... - CSZ News (NASDAQ:RTRX) - October 16 at 11:26 AM
News IconShare Value Diminishing Over Past Month: Retrophin, Inc. (NASDAQ:RTRX) - CSZ News (NASDAQ:RTRX) - October 15 at 6:43 PM
News IconEarnings Reaction History: Retrophin, Inc. (NASDAQ:RTRX) has a ... - The Independent Republic (NASDAQ:RTRX) - October 15 at 11:51 AM
News IconRetrophin, Inc. (RTRX) Updated Broker Price Targets - The De Soto Edge (NASDAQ:RTRX) - October 13 at 10:50 AM logoRetrophin Inc (NASDAQ:RTRX) Files An 8-K (NASDAQ:RTRX) - October 9 at 11:15 AM logoRetrophin's (RTRX) Head of R&D to Resign - (NASDAQ:RTRX) - October 8 at 11:36 AM logoDr. Alvin Shih Departing Retrophin to Lead Biotechnology Start-Up - GlobeNewswire (press release) (NASDAQ:RTRX) - October 7 at 6:49 PM logoDr. Alvin Shih Departing Retrophin to Lead Biotechnology Start-Up (NASDAQ:RTRX) - October 6 at 6:51 PM
News IconTop Earnings to Watch for: Retrophin, Inc. (NASDAQ:RTRX) - The Voice Registrar (NASDAQ:RTRX) - October 5 at 6:59 PM
News IconRetrophin, Inc. (RTRX) Analyst Review - NewsDen (NASDAQ:RTRX) - October 3 at 6:40 PM logoRetrophin Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:RTRX) - October 1 at 8:37 AM
News IconBroker Roundup For Retrophin, Inc. (RTRX) - The De Soto Edge (NASDAQ:RTRX) - September 30 at 3:41 PM
News IconRetrophin, Inc. (RTRX) Latest Broker Coverage - NewsDen (NASDAQ:RTRX) - September 28 at 12:20 PM logoHealth Care Stocks Bound for Declines After 2016 Election (NASDAQ:RTRX) - September 22 at 6:49 PM
News IconRetrophin Inc. (RTRX) Stock Price Down 2.6% - NewsDen (NASDAQ:RTRX) - September 20 at 12:24 PM
News IconRetrophin Inc (RTRX) Receives Buy Rating from BMO Capital Markets - DailyQuint (NASDAQ:RTRX) - September 19 at 7:01 PM logoRetrophin : to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series (NASDAQ:RTRX) - September 15 at 7:13 PM
News IconRetrophin To Present At The (NASDAQ:RTRX) - September 15 at 7:13 PM logoRetrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series (NASDAQ:RTRX) - September 14 at 7:18 PM
News IconRetrophin Inc. (NASDAQ: RTRX) Outperform Rating Reiterated at JMP Securities - BNB Daily (blog) (NASDAQ:RTRX) - September 14 at 11:31 AM logoMartin Shkreli Will Be A Guest On PreMarket Prep Tomorrow (NASDAQ:RTRX) - September 11 at 6:32 PM
News IconRetrophin Inc. (NASDAQ: RTRX) stock reiterated at BMO Capital ... - BNB Daily (blog) (NASDAQ:RTRX) - September 9 at 6:46 PM logoBiotech Movers: Retrophin Inc (RTRX) and Agios Pharmaceuticals Inc (AGIO) - Insider Monkey (blog) (NASDAQ:RTRX) - September 9 at 6:46 PM logoRetrophin, Inc. – Value Analysis (NASDAQ:RTRX) : September 9, 2016 (NASDAQ:RTRX) - September 9 at 6:46 PM logoHere's Why Leerink Partners Raised Retrophin Inc's (RTRX) Price Target to $32 - TCC (NASDAQ:RTRX) - September 9 at 11:55 AM logoRetrophin, Inc.: Gathering momentum, can it sustain its performance? (NASDAQ:RTRX) - September 8 at 6:50 PM logoRetrophin Inc (RTRX) Options Explode on Upbeat Drug Data - Schaeffers Research (blog) (NASDAQ:RTRX) - September 8 at 10:58 AM logoRetrophin Inc (RTRX) Has Over 90% Upside Potential: BMO Capital - TCC (NASDAQ:RTRX) - September 8 at 10:58 AM logoRetrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : September 8, 2016 (NASDAQ:RTRX) - September 8 at 10:58 AM
News IconNASDAQ Composite Index Makes 2nd-Straight Closing & Intra-Day Record in as Many Days (NASDAQ:RTRX) - September 7 at 7:16 PM logoRetrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His $25+ Million 'Hogan Reward' (NASDAQ:RTRX) - September 7 at 7:16 PM logoRetrophin Inc (RTRX) Options Explode on Upbeat Drug Data (NASDAQ:RTRX) - September 7 at 7:16 PM logoRetrophin Reports Positive Top-line Results From Sparsentan Phase 2 DUET Study (NASDAQ:RTRX) - September 7 at 10:46 AM logoRetrophin Inc. (RTRX) Is Up Sharply On Phase 2 Study Results (NASDAQ:RTRX) - September 7 at 10:46 AM logoRetrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease (NASDAQ:RTRX) - September 7 at 10:46 AM logoWhy Retrophin Shares Have Soared (NASDAQ:RTRX) - September 7 at 10:46 AM logoUS STOCK-Wall St to open flat as investors seek clues on rates (NASDAQ:RTRX) - September 7 at 10:46 AM logoETF’s with exposure to Retrophin, Inc. : September 6, 2016 (NASDAQ:RTRX) - September 6 at 11:53 AM
News IconCompany that price gouged EpiPen is Clinton Foundation donor (NASDAQ:RTRX) - September 5 at 11:13 AM logoRetrophin: Another Promising Core Plus Biotech Gem - Seeking Alpha - Seeking Alpha (NASDAQ:RTRX) - August 31 at 12:26 PM
News IconTuring accused of retaliation after executive's sexual assault complaint (NASDAQ:RTRX) - August 24 at 6:55 PM logoWhat Will Retrophin Inc (NASDAQ:RTRX) Get For Its Money On A Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Deal? (NASDAQ:RTRX) - August 19 at 7:04 PM
News IconTakeover Rumors Around Raptor Pharmaceutical (RPTP); Bullish View On Digital Ally (DGLY) (NASDAQ:RTRX) - August 18 at 7:29 PM logoRaptor Pharmaceutical : Retrophin Reportedly Considers Bid For Raptor Pharma (NASDAQ:RTRX) - August 18 at 10:14 AM logoRetrophin Reportedly Considers Bid For Raptor Pharma (NASDAQ:RTRX) - August 18 at 10:14 AM


Retrophin (NASDAQ:RTRX) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff